PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease

  • Collaboration with Biogen will leverage TRIMTECH’s proprietary TRIM21-based targeted protein degradation technology to develop novel protein degrading therapeutics for neurodegenerative diseases.
  • Includes up to $32 million in upfront and research milestone payments, with total potential payments of up to $411 million, plus royalties.

TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has entered into a strategic research collaboration, option, and license agreement with Biogen International GmbH.

Under the terms of the agreement, Biogen and TRIMTECH will work collaboratively to discover and develop small molecule protein degraders for the treatment of neurodegenerative diseases. Upon Biogen’s exercise of the option, the company will be granted a global exclusive license to the degraders developed and will be responsible for further development and commercialisation activities. Under the terms of the agreement, TRIMTECH is eligible to receive up to $32 million in upfront and research milestone payments, with total potential payments of up to $411 million, plus royalties.

Dr Nicki Thompson, CEO, TRIMTECH Therapeutics, said: “We are excited to enter this strategic collaboration with Biogen, which is a major milestone for TRIMTECH. This is a significant validation of the progress we have made and the potential of our TRIM21-based targeted protein degradation platforms. Combining our expertise with Biogen’s strong legacy and experience in developing treatments for neurodegenerative diseases brings new promise to the potential of delivering more effective therapies for patients.“

Founded on decades of pioneering academic research into the protein TRIM21, a novel E3-ligase, TRIMTECH has demonstrated its small molecule TRIMTAC® and TRIMGLUE® degraders can access the CNS and selectively degrade toxic protein aggregates and oligomers underpinning many neurodegenerative diseases. This opens-up much needed small molecule treatment options and offers the potential to transform the course of treatment for the millions of patients battling these diseases.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC